GlassScriptPhysician profile
Mitchell Jason Marder
NPI 1285673319
$1,614.95
in general payments reported to CMS, 2019-2025
21 companies · $39.31 in 2025
The $39.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $240 · 2021: $172 · 2022: $82.37 · 2023: $21.58 · 2024: $14.54 · 2025: $39.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $246.70 | 2019-2025 | Shingrix, Arexvy |
| Abbvie INC. | $214.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $192.32 | 2019-2020 | |
| Pfizer INC. | $143.21 | 2019-2020 | |
| Lilly USA, LLC | $121.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.59 | 2019-2020 | |
| Novo Nordisk INC | $111.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.51 | 2019-2025 | Jardiance |
| Allergan, INC. | $64.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $47.64 | 2019 | |
| Arbor Pharmaceuticals, INC. | $35.40 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $31.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.74 | 2019 | |
| Daiichi Sankyo INC. | $24.15 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Amarin Pharma, INC. | $19.28 | 2020 | |
| Horizon Therapeutics Plc | $19.12 | 2022 | |
| Janssen Biotech, INC. | $17.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Marder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.